ClinicalTrials.gg
RecruitingNCT07134686CON-POUpdated Aug 3, 2026

Implementation of a Joint Pulmonologist and ENT Consultation in the Care Pathway of Patients Suffering From Asthma and Chronic Rhinosinusitis With Nasal Polyposis: Effectiveness Compared With Consultations by Specialty (CON-PO Study).

An interventional study of Joint consultation and Mucus sampling in Asthma and Chronic Rhinosinusitis With Nasal Polyps (CRSwNP), sponsored by Assistance Publique Hopitaux De Marseille. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by Assistance Publique Hopitaux De Marseille · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
195
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 296 studies in Asthma with a site in France — 44 open to participants now, 57 under way, 8 of them phase 3. Asthma · France.

Planned enrollment
108th of 204
195 · median 209
Started
2026
with 9 others
No phase
63 of 296
17 open now
Primary completion
2029-11
later than 51 of 56 live
Registered
285th of 296
by date

Among the 296 studies in Asthma with a site in France, this one is the 108th largest by planned enrollment of the 204 interventional ones that give a count, is one of 10 that started in 2026, is one of 63 with no phase, reaches primary completion later than 51 of the 56 other live ones, and was the 285th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

44 of the 296 studies in Asthma with a site in France are open now. Recruiting first, the newest first:

38 more — sign in →

All 44 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 296 studies in Asthma with a site in France, or all of them as a file.
02

Study summary

Asthma affects the lower respiratory tract (bronchi), whereas chronic rhinosinusitis with nasal polyposis (CRSwNP) involves the upper airways. Despite this anatomical distinction, the upper and lower airways form a continuous respiratory tract and share common pathophysiological mechanisms. Consequently, asthma and CRSwNP frequently coexist, and several therapeutic strategies are effective for both conditions.

Given these overlaps, we hypothesize that a multidisciplinary consultation involving both a pulmonologist and an ENT specialist could be more effective than separate consultations for patient care. We also believe that this innovative organization that would benefit the healthcare system.

To test this hypothesis, we are conducting a study whose primary objective is to assess whether joint consultations lead to a reduction in oral corticosteroid need over the year following the initial consultation, by enabling more personalized treatment strategies.

Secondary outcomes will include the frequency of asthma exacerbations, frequency of ENT-related events, respiratory symptoms, quality of life, and healthcare ressources utilization.

We will compare outcomes between two patient groups: one receiving joint consultation from both specialists, and the other managed through standard, separate consultations as per current clinical practice.

03

Conditions studied

  • Asthma
  • Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

Browse trials for

Keywords

  • Asthma
  • Care pathway
  • Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, 18 years of age or older;
  • With a diagnosis of asthma;
  • With a diagnosis of chronic rhinosinusitis with nasal polyposis;
  • Whose asthma and/or chronic rhinosinusitis is/are not controlled according to SNOT-22 and ACQ-6 scores;
  • Having used systemic in the previous year to treat symptoms related to one of these conditions at least;

Exclusion criteria

Exclusion Criteria:

  • Patient in a period of exclusion from another research protocol at the time of consent signature;
  • Subjects covered by articles L1121-5 to 1121-8 of the French Public Health Code (adult patients under guardianship or curatorship, patients deprived of their liberty, pregnant or breast-feeding women);
  • Patients who do not read and/or understand French
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
195 participants (estimated)

Study arms

  • Experimental
    Joint consultation

    Multi-disciplinary consultation with a pulmonologist and ENT specialist at the baseline visit

    Other: Joint consultation · Procedure: Mucus sampling · Procedure: Nasal brushing

  • Active comparator
    Separate consultations

    Separate consultations with a pulmonologist and ENT specialist at the baseline visit as standard care

    Procedure: Mucus sampling · Procedure: Nasal brushing

Interventions

  • OtherJoint consultation

    Joint consultation with pneumologist and ENT at baseline.

  • ProcedureMucus sampling

    Mucus sampling at baseline and one year follow-up

  • ProcedureNasal brushing

    Nasal brushing at baseline and one year follow-up

06

What researchers measure

Primary outcomes

  1. Effectiveness of joint ENT and pulmonologist consultation on relative change in cumulative annual dose of oral corticosteroids from the year before Baseline to the year between Baseline and 12 months visit.

    Self reported cumulative annual dose of oral corticosteroids.

    Time frame: From the year before Baseline to the 12 months visit.

Secondary outcomes

  1. Reduction of asthma exacerbations frequency. Relative change from the year before Baseline to the year between baseline and 12 months visit in number of asthma exacerbations.

    self-reported number of asthma exacerbations

    Time frame: From the year before Baseline to the 12 months visit.

  2. Reduction of ENT events frequency. Relative change from the year before baseline to the year between baseline and 12 month visit in number of ENT events.

    Self reported number of ENT events

    Time frame: From the year before Baseline to the 12 months visit.

  3. Improvement of asthma control. Relative change from baseline to 12 months visit in ACQ-6 score

    Self-administered questionnaire

    Time frame: Baseline and 12 months visit.

  4. Improvement of chronic rhinosinusitis with nasal polyposis control . Relative change from baseline to 12 months visit in SNOT-22 score

    Self-administered questionnaire

    Time frame: Baseline and 12 months visit.

  5. Reduction in endoscopic polyp score. Relative change from baseline to 12 months visit in the polyp endoscopic score (mean of measures of both nostrils)

    Evaluated with nasal endoscopy

    Time frame: Baseline and 12 months visit.

  6. Improvement of patient's quality of life. Relative change from baseline to 12 months visit in EQ-5D-5L score

    Self-administered questionnaire

    Time frame: Baseline and 12 months visit.

  7. Reduction of healthcare ressource use . Relative change from baseline to 12 months visit in number of consultations with a specialist, general practitionner, emergency visits and hospitalizations

    Self-reported number of consultations with a specialist, general practicionner, emergency visits and hospitalizations

    Time frame: From Baseline to the 12 months visit

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Nov 2029, 40 months after the start.

Of 601 non-industry interventional studies with no phase under Asthma, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 50. This study's planned 40 months is above that.

Counting every sponsor, half of 651 studies reached it within 23 months; a quarter within 10 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2025
First posted
Aug 21, 2025
StartActual
Jul 28, 2026
Primary completionEst.
Nov 2029
CompletionEst.
Nov 2029
Last update
Aug 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07134686
Responsible party
Sponsor
First posted
Aug 21, 2025
Start date
Jul 28, 2026
Primary completion
Nov 2029 (estimated)
Completion
Nov 2029 (estimated)
Last update
Aug 3, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion